Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

Research Watch

IDH Mutations Promote Glioma through Epigenetic Insulator Disruption

DOI: 10.1158/2159-8290.CD-RW2016-003 Published February 2016
  • Article
  • Info & Metrics
  • PDF
Loading
  • Major finding: Disrupted CTCF binding at the PDGFRA boundary element enhances its expression, promoting glioma growth.

  • Mechanism: IDH mutations disrupt insulator elements by promoting CTCF binding site hypermethylation.

  • Impact: Activation of oncogenes by the disruption of chromosomal topology may occur in other tumor settings.

Gain-of-function mutations in isocitrate dehydrogenase (IDH) lead to the production of 2-hydroxyglutarate, which disrupts the activity of the TET family DNA demethylases and thus can contribute to CpG island hypermethylation. However, the functional relevance of enhanced CpG methylation in glioma is not well understood. CCCTC-binding factor (CTCF) is a methylation-sensitive insulator protein involved in creating chromatin boundaries. To determine if IDH-dependent hypermethylation altered CTCF binding, Flavahan, Drier, and colleagues performed CTCF chromatin immunoprecipitation sequencing (ChIP-seq) of gliomas, and obtained DNA methylation profiles from The Cancer Genome Atlas. CTCF occupancy was reduced at more sites than it was increased in IDH-mutant gliomas, and the CTCF-deficient sites had higher GC content and increased DNA methylation than IDH–wild-type gliomas. Based on constitutive domain boundaries and RNA-seq data, IDH mutant gliomas had an increased correlation between genes normally insulated from each other by topological domain boundaries. The increased correlation raised the possibility that reduced CTCF binding in IDH-mutant gliomas may disrupt topological domain boundaries. Approximately 200 domain boundaries disrupted by IDH mutation were identified, and genes located adjacent to these boundaries showing increased expression in IDH-mutant gliomas included known glioma oncogenes such as PDGFRA. In IDH-mutant gliomas, PDGFRA expression was correlated with expression of FIP1L1, a housekeeping gene normally located in a distinct domain separated from PDGFRA by a CTCF-bound constitutive boundary. In IDH-mutant gliomas, CTCF occupancy at this boundary was reduced, and the PDGFRA promoter interacted with the FIP1L1 enhancer instead of its cognate enhancer as in IDH–wild-type glioma. Treatment with the DNA methyltransferase inhibitor 5-azacytidine reduced methylation of the CTCF motif, increased CTCF binding, and downregulated PDGFRA. Conversely, CRISPR-mediated disruption of the CTCF boundary element also increased PDGFRA expression, and promoted glioma cell growth. Altogether, these findings demonstrate that IDH mutations can promote glioma growth through disruption of boundary elements and impaired oncogene insulation.

Flavahan WA, Drier Y, Liau BB, Gillespie SM, Venteicher AS, Stemmer-Rachamimov AO, et al. Insulator dysfunction and oncogene activation in IDH mutant gliomas. Nature 2016;529:110–4.

Notes

Note: Research Watch is written by Cancer Discovery editorial staff. Readers are encouraged to consult the original articles for full details. For more Research Watch, visit Cancer Discovery online at http://cancerdiscovery.aacrjournals.org/content/early/by/section.

  • ©2016 American Association for Cancer Research.
PreviousNext
Back to top
Cancer Discovery: 6 (2)
February 2016
Volume 6, Issue 2
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
IDH Mutations Promote Glioma through Epigenetic Insulator Disruption
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
IDH Mutations Promote Glioma through Epigenetic Insulator Disruption
Cancer Discov February 1 2016 (6) (2) 119; DOI: 10.1158/2159-8290.CD-RW2016-003

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
IDH Mutations Promote Glioma through Epigenetic Insulator Disruption
Cancer Discov February 1 2016 (6) (2) 119; DOI: 10.1158/2159-8290.CD-RW2016-003
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Notes
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

Research Watch

  • Structures Identify Selpercatinib and Pralsetinib Resistance Mechanisms
  • Cryo-EM Structures Reveal Mechanism of Anticancer MCT1 Inhibitors
  • Computational Tool Characterizes Previously Unidentified Tumor Subtypes
Show more Research Watch

Glioma

  • Distinct Transitional States of Glial Progenitors Drive Gliomagenesis
  • Unique Molecular Landscapes Distinguish Low- and High-Grade NF1 Gliomas
  • (R)-2HG Inhibits the BCAT Transaminase in IDH-Mutant Glioma
Show more Glioma
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement